Buradasınız

Anasayfa » Content

FEBRİL NÖTROPENİLİ HASTALARDA AMPİRİK ANTİBİYOTİK REJİMLERİNİN ETKİNLİKLERİNİN KARŞILAŞTIRILMASI

The comparison of the efficacy of empirical antibiotic regimens in febrile neutropenic patients

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2000

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objectives: To compare of the efficacy of empirical antibiotic regimens in febrile neutropenic patients in in Adult Hematology Clinic of Turgut Ozal Medical Center. Material and methods: Four different antibiotic regimens Ceftazidime+Amikacin (n=19), Imipenem+Amikacin (n=14), Cefepime+Amikacin (n=20) and Sulbactam/Cefoperozone+Ami-kacin (n=20) were assessed as initial empirical therapy in febrile neutropenic patients. Results: Seventy-three febrile neutropenic episodes in 43 patients were evaluated. There was no significant difference in the efficacy and toxicity of antibiotics between the four different regimens (p>0.05). Conclusion: All of the four empirical antibiotic regimens were equally effective and well tolerated as initial therapy for neutropenic patients with fever.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Turgut Özal Tıp Merkezi erişkin Hematoloji kliniğindeki febril nötropenik hastalarda ampirik tedavi rejimlerinin etkinliklerinin karşılaştırılması. Materyal ve metot: Dört farklı antibiyotik rejimi, Seftazidim+Amikasin (n=19), İmipenem+ Arnikasın (n=14), Sefepim+Amikasin (n=20), Sulbaktam/Sefoperazon+Amikasin (n=20) karşılaştırıldı. Kırk üç hastada gelişen toplam 73 febril nötropenik atak değerlendirildi. Bulgular: Dört farklı antibiyotik rejimi alan gruplar arasında etkinlik ve toksite açısından fark yoktu (p>0.05). Sonuç: Her dört rejim de toksisite ve etkinlik açısından febril nötropenik hastalarda başlangıç tedavisinde kullanılabileceği görüşüne varıldı.
FULL TEXT (PDF): 
PDF icon arastirmax-febril-notropenili-hastalarda-ampirik-antibiyotik-rejimlerinin-etkinliklerinin-karsilastirilmasi.pdf
  • 1
19-23
  • Turkish

REFERENCES

References: 

1. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;18:1323-32.
2. Klastersky J. Therapy of infections in cancer patients. In: Klastersky J, Schimpff SC, Senn H-J (eds). Handbook of Supportive Care in Cancer. New York: Marcel Dekker, Inc, 1995:1-44.
3. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever: a statement by the Infectious Diseases Society of America. J Infect Dis 1990;161:381-2.
4. Uzun Ö, Akova M, Hayran M, et al. Empiric antimicrobial therapy in febrile granulocytopenic patients. Turkish J Cancer 1992;2:73-7.
5. Klastersky J. Concept of empiric therapy with antibiotic combinations. Am J Med 1986;80(suppl. 5C):2-12.
6. Klastersky J. Empirical antibiotic therapy in neutropenic cancer patients. Eur J Cancer 1993;29 (suppl.l): 6-10.
7. Liang R, Yung R, Chifu E, et al. Ceftazidime versus Imipenem-Cilastatin as initial monotherapy for febrile neutropenic patients. Antimicrobial Agents and Chemother 1990;34:1336-41.
8. Lee JW, Pizzo PA. Management of cancer patient with fever and prolonged neutropenia. Hematol Oncol Clin North Am 1993;7:937-9.
9. Buchanan GR. Approach to treatment of the febrile cancer patients with low risk neutropenia. Hematol Oncol Clin North Am 1993;7:919-21.
10. Dranitsaris G. Clinical and economic considerations of empirical antibacterial therapy of febril neutropenia in cancer. Pharmacoeconomics 1999;16:343-53.
11. Masaoka T. Febrile neutropenia-guideline in Japan. Gan To Kagaku Ryoho 2000;27:161-5.
12. Jarque I, Sanz MA. Application of the concepts of evidence-based medicine to the evidence on the treatment
of febrile neutropenia. Enferm Infecc Microbiol Clin 1999;17 Suppl 2:95-102.
13. Antabli BA, Bross P, Siegel RS, Small CD, Tabbara IA. Empiric antimicrobial therapy of febrile neutropenic patients undergoing haematopoietic stem cell transplantation. Int J Antimicrob Agents 1999;13:127-30.
14. Akova M, Akan H, Korten V, Biberoglu K, Hayran M, Ünal S, Kars A, Kansu E. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey. Int J Antimicrob Agents 1999;13:15-9.
15. Akova
M
, Akalın HE. Nötropenik hastalarda ateş. Hacettepe Tıp Dergisi 1988;21:71-3.
16. Schimpff SC. Growth factors and empiric therapy with antibiotics: Should they be used concurrently? Ann Intern Med 1994;121:538-41.
17. European Organization for Research and Treatment of Cancer (EORTC), International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991;163:951-4.

Thank you for copying data from http://www.arastirmax.com